Title
Comparison of intralesional 5-fluorouracil versus intralesional triamcinolone acetonide for keloid treatment: A prospective randomised double-blind controlled study
Authors
Vishwa Deep & Prabhat Shrivastava*
Affiliation
Department of Burns and Plastic Surgery, Lok Nayak Hospital and associated Maulana Azad Medical College, New Delhi-110002, India; *Corresponding author
Vishwadeep - E-mail: vishwa2k2@gmail.com;
+917206645263
Prabhat Shrivastava - E-mail: drpsacademics@gmail.com; +919729978886
Article Type
Research Article
Date
Received February 1, 2026; Revised February 28, 2026; Accepted February 28, 2026, Published February 28, 2026
Abstract
Keloid scars pose significant treatment challenges due to excessive collagen deposition, causing pain, functional impairment and psychological distress despite multiple available interventions. Therefore, it is of interest to compare intralesional 5-fluorouracil (5-FU, 50 mg/mL) versus triamcinolone acetonide (40 mg/mL) in 30 patients randomly assigned to two equal groups. Vancouver Scar Scale parameters (height, pliability, vascularity, pigmentation), pain (Visual Analogue Scale) and pruritus were assessed at treatment end and 2-month follow-up. Both treatments achieved significant VSS improvement (p<0.001), with 93.3% 5-FU and 100% triamcinolone patients reaching total VSS ≤5; 5-FU showed faster response (40% endpoint by session 5 vs 20%) and fewer adverse reactions. Intralesional 5-FU emerges as a superior, less toxic alternative to triamcinolone for keloid management, offering equivalent efficacy with quicker clinical response and better safety profile.
Keywords
Keloid, 5-fluorouracil, triamcinolone acetonide, intralesional injection, Vancouver scar scale, wound healing
Citation
Deep & Shrivastava, Bioinformation 22(2): 1244-1249 (2026)
Edited by
Vini Mehta
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
